2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
From PRMT5 inhibitors to ADC-bispecific combos and Japan’s domestic push, emerging modalities are driving the next wave of innovation. The race is on to capture breakthroughs that could redefine treatment worldwide.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.
Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.
